Zacks Research Downgrades Alto Neuroscience (NYSE:ANRO) to Strong Sell

Alto Neuroscience (NYSE:ANRO) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

ANRO has been the subject of several other reports. Wolfe Research assumed coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Bank of America assumed coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price for the company. Robert W. Baird dropped their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, Wedbush raised their price target on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Trading Down 1.5%

Shares of ANRO opened at $26.81 on Wednesday. Alto Neuroscience has a fifty-two week low of $2.97 and a fifty-two week high of $28.85. The firm has a market cap of $940.76 million, a price-to-earnings ratio of -11.08 and a beta of 1.04. The firm has a 50 day moving average price of $23.39 and a 200-day moving average price of $21.46. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities research analysts forecast that Alto Neuroscience will post -3.01 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its position in shares of Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after acquiring an additional 211,222 shares during the period. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the first quarter valued at about $8,687,000. Artia Global Partners LP purchased a new stake in shares of Alto Neuroscience during the fourth quarter worth about $520,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience during the first quarter worth about $538,000. Finally, Perceptive Advisors LLC grew its stake in shares of Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.